zamicastat

Dopamine beta-hydroxylase (DBH) inhibitor that has limited access to the brain

Also Known As:

5-(2-(Benzylamino)ethyl)-1-((3R)-6,8-difluoro-3,4-dihydro-2H-chromen-3-yl)-1,3-dihydro-2H-imidazole-2-thione

Networked: 4 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Imidazoles: 150
      - zamicastat: 4
  - Pyrans: 130
    - Benzopyrans: 195
      - zamicastat: 4
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzopyrans: 195
      - zamicastat: 4

Experts

1.	Soares-da-Silva, Patrício: 3 articles (10/2019 - 05/2018)
2.	Igreja, Bruno: 2 articles (10/2019 - 01/2019)
3.	Dey, Sanjay Kumar: 1 article (09/2020)
4.	Kundu, Suman: 1 article (09/2020)
5.	Prabhakar, Pankaj: 1 article (09/2020)
6.	Saini, Manisha: 1 article (09/2020)
7.	Loureiro, Ana: 1 article (10/2019)
8.	Pires, Nuno: 1 article (10/2019)
9.	Wright, Lyndon: 1 article (10/2019)
10.	Pires, Nuno M: 1 article (01/2019)

Related Diseases

1.	Hypertension (High Blood Pressure) 09/01/2020 - "Inhibitors of DBH have been successful in combating hypertension, as evidenced by the outcome of clinical trials for etamicastat and zamicastat. " 01/05/2019 - "The use of DβH inhibitors, like zamicastat, is a promising approach to treat hypertension, heart failure and cardiovascular diseases where a reduction in the sympathetic tone has beneficial effects." 01/05/2019 - "Zamicastat (10, 30 and 100 mg/kg body weight) was tested acutely against salt-induced hypertension in the Dahl SS rat. " 01/05/2019 - "Effects of zamicastat treatment in a genetic model of salt-sensitive hypertension and heart failure." 01/05/2019 - "The aim of the present study was to evaluate the effects of zamicastat, a novel DβH inhibitor that decreases noradrenaline and increases dopamine levels in peripheral sympathetically innervated tissues, on the hemodynamic and cardiometabolic parameters in salt-induced hypertension and heart failure in the Dahl salt-sensitive (SS) rat. "
2.	Heart Failure 01/05/2019 - "The use of DβH inhibitors, like zamicastat, is a promising approach to treat hypertension, heart failure and cardiovascular diseases where a reduction in the sympathetic tone has beneficial effects." 01/05/2019 - "Effects of zamicastat treatment in a genetic model of salt-sensitive hypertension and heart failure." 01/05/2019 - "The aim of the present study was to evaluate the effects of zamicastat, a novel DβH inhibitor that decreases noradrenaline and increases dopamine levels in peripheral sympathetically innervated tissues, on the hemodynamic and cardiometabolic parameters in salt-induced hypertension and heart failure in the Dahl salt-sensitive (SS) rat. "
3.	Breast Neoplasms (Breast Cancer) 05/30/2018 - "Thus, the purpose of the study herein presented was to explore the interaction of P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP), the two major efflux transporters of the BBB that hamper the entry of several drugs to the brain, with the DBH inhibitors, etamicastat, nepicastat and zamicastat. "
4.	Body Weight (Weight, Body) 10/11/2019 - "Zamicastat-induced sympathetic down-regulation decreased the high BP in SHRs, with no observed effect on HR. The heart-to-body weight ratio was lower in SHRs treated with zamicastat, whereas the body weight and kidney-to-body weight ratio were similar between both SHR cohorts. " 01/05/2019 - "Zamicastat (10, 30 and 100 mg/kg body weight) was tested acutely against salt-induced hypertension in the Dahl SS rat. "
5.	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/05/2019 - "Prolonged treatment with zamicastat ameliorated end-organ damage, metabolic syndrome and inflammation hallmarks in hypertensive Dahl SS rats. "

Related Drugs and Biologics

1.	etamicastat
2.	Member 1 Subfamily B ATP Binding Cassette Transporter
3.	Salts
4.	Proteins (Proteins, Gene)
5.	Norepinephrine (Noradrenaline)
6.	Dopamine (Intropin)
7.	nepicastat
8.	Biomarkers (Surrogate Marker)